TY - JOUR
T1 - The International Association for the Study of Lung Cancer Staging Project
T2 - Methods and Guiding Principles for the Development of the Ninth Edition TNM Classification
AU - the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and Advisory Boards
AU - Detterbeck, Frank C.
AU - Nishimura, Katherine K.
AU - Cilento, Vanessa J.
AU - Giuliani, Meredith
AU - Marino, Mirella
AU - Osarogiagbon, Raymond U.
AU - Rami-Porta, Ramon
AU - Rusch, Valerie W.
AU - Asamura, Hisao
N1 - Funding Information:
The work of Dr. Valerie Rusch is supported in part by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.
Funding Information:
Disclosure: Dr. Nishimura reports statistical consulting by Cancer Research And Biostatistics (CRAB) employees for manuscripts related to the staging project is funded by the International Association for the Study of Lung Cancer (IASLC); statistical consulting by CRAB employees for data collection and analysis in the staging project is funded by IASLC; consulting fees—statistical consulting by CRAB employees for the staging project is funded by the IASLC; support for attending meeting and/or travel per IASLC contract with CRAB includes funds to attend the World Conference on Lung Cancer conference to participate in staging project meetings. Dr. Giuliani reports receiving personal payment for consulting fees from Bristol-Myers Squibb and honoraria fees from AstraZeneca and Bristol-Myers Squibb for lectures. Dr. Osarogiagbon reports receiving funding support for R01CA172253; consulting fees from the National Institutes of Health National Cancer Institute Division of Cancer Control and Population Sciences Health Systems and Interventions Research Branch, American Cancer Society, Association of Community Cancer Centers, AstraZeneca, Memorial Sloan Kettering Cancer Center, Druckenmiller Center for Lung Cancer Research, Genentech/Roche, and Tryptych Health Partners; honoraria fees from Biodesix and Medscape for lectures; patents planned, issued, or pending for three issued patents for a lymph node specimen collection kit: two United States, one People's Republic of China; reports being on the following boards—Board Chair, Hope Foundation for Cancer Research, Member, LUNGevity Health Equity Council, Steering Committee, National Lung Cancer Round Table, Co-Chair Ad hoc Committee on Diversity and Inclusion, Fleischner Society, Member, and GO2 Foundation Scientific Advisory Board; reports stock or stock options with Eli Lilly, Gilead Sciences, and Pfizer. Dr. Rusch reports receiving institutional grants to support clinical trials from Genelux, Inc., and Genentech; travel reimbursement only for robotic teaching session in 2019 from Intuitive Surgical; is a Member, Data Safety Monitoring Committee MARS II Trial, United Kingdom, but received no reimbursement; is a Co-Chair, Thoracic Malignancy Stating Committee, National Cancer Institute/National Institutes of Health and receives travel and meeting preparation reimbursement. Dr. Asamura reports receiving grants from the following: Taiho Pharmaceutical, Johnson and Johnson, Covidien, Astellas, Eli Lilly & Co, AstraZeneca, and Chugai. The remaining authors declare no conflict of interests.
Funding Information:
Disclosure: Dr. Nishimura reports statistical consulting by Cancer Research And Biostatistics (CRAB) employees for manuscripts related to the staging project is funded by the International Association for the Study of Lung Cancer (IASLC); statistical consulting by CRAB employees for data collection and analysis in the staging project is funded by IASLC; consulting fees—statistical consulting by CRAB employees for the staging project is funded by the IASLC; support for attending meeting and/or travel per IASLC contract with CRAB includes funds to attend the World Conference on Lung Cancer conference to participate in staging project meetings. Dr. Giuliani reports receiving personal payment for consulting fees from Bristol-Myers Squibb and honoraria fees from AstraZeneca and Bristol-Myers Squibb for lectures. Dr. Osarogiagbon reports receiving funding support for R01CA172253; consulting fees from the National Institutes of Health National Cancer Institute Division of Cancer Control and Population Sciences Health Systems and Interventions Research Branch, American Cancer Society, Association of Community Cancer Centers, AstraZeneca, Memorial Sloan Kettering Cancer Center, Druckenmiller Center for Lung Cancer Research, Genentech/Roche, and Tryptych Health Partners; honoraria fees from Biodesix and Medscape for lectures; patents planned, issued, or pending for three issued patents for a lymph node specimen collection kit: two United States, one People’s Republic of China; reports being on the following boards—Board Chair, Hope Foundation for Cancer Research, Member, LUNGevity Health Equity Council, Steering Committee, National Lung Cancer Round Table, Co-Chair Ad hoc Committee on Diversity and Inclusion, Fleischner Society, Member, and GO2 Foundation Scientific Advisory Board; reports stock or stock options with Eli Lilly, Gilead Sciences, and Pfizer. Dr. Rusch reports receiving institutional grants to support clinical trials from Genelux, Inc., and Genentech; travel reimbursement only for robotic teaching session in 2019 from Intuitive Surgical; is a Member, Data Safety Monitoring Committee MARS II Trial, United Kingdom, but received no reimbursement; is a Co-Chair, Thoracic Malignancy Stating Committee, National Cancer Institute/National Institutes of Health and receives travel and meeting preparation reimbursement. Dr. Asamura reports receiving grants from the following: Taiho Pharmaceutical , Johnson and Johnson , Covidien , Astellas , Eli Lilly & Co , AstraZeneca , and Chugai . The remaining authors declare no conflict of interests.
Publisher Copyright:
© 2022
PY - 2022/6
Y1 - 2022/6
N2 - Introduction: Stage classification provides a consistent and concise nomenclature about the anatomic extent of the cancer. This is a fundamental cornerstone in the management of patients; it enables reporting results and facilitates comparing one treatment to another and judging how closely clinical trial results apply to an individual patient. A nomenclature must be relatively static; however, periodical refinement is needed to adjust to a changing landscape of clinical relevance. Changes must be well justified and thoughtfully developed to maintain the ability to communicate clearly and facilitate comparisons across time. Methods: For thoracic malignancies (lung, pleura, thymus, and esophagus), the International Association for the Study of Lung Cancer (IASLC) has leveraged its worldwide multidisciplinary reach, permitting a sophisticated approach to this process. Refinement of stage classification for the ninth edition of TNM is underway; this article describes the approach adopted by the IASLC Staging and Prognostic Factors Committee. Results: Key guiding principles include the ability to maintain communication over time, a classification that discriminates homogeneous cohorts of tumors consistently across the world in multiple settings, treatment approaches, and patient characteristics, including clinical relevance and practical applicability. The IASLC has again assembled a large international database to permit multifaceted analysis. Providing confidence that the classification performs consistently in multiple settings, treatments, and patients requires consistent discrimination in multiple subset analyses. Although observed outcomes of patients in the 2011 to 2019 database are essential, considerations about how the classification will be used are also important to ensure clinical relevance and applicability. Conclusions: The strategy developed by the Staging and Prognostic Factors Committee is carefully designed to provide useful refinements to the stage classification of thoracic malignancies for the ninth edition of TNM classification of cancers.
AB - Introduction: Stage classification provides a consistent and concise nomenclature about the anatomic extent of the cancer. This is a fundamental cornerstone in the management of patients; it enables reporting results and facilitates comparing one treatment to another and judging how closely clinical trial results apply to an individual patient. A nomenclature must be relatively static; however, periodical refinement is needed to adjust to a changing landscape of clinical relevance. Changes must be well justified and thoughtfully developed to maintain the ability to communicate clearly and facilitate comparisons across time. Methods: For thoracic malignancies (lung, pleura, thymus, and esophagus), the International Association for the Study of Lung Cancer (IASLC) has leveraged its worldwide multidisciplinary reach, permitting a sophisticated approach to this process. Refinement of stage classification for the ninth edition of TNM is underway; this article describes the approach adopted by the IASLC Staging and Prognostic Factors Committee. Results: Key guiding principles include the ability to maintain communication over time, a classification that discriminates homogeneous cohorts of tumors consistently across the world in multiple settings, treatment approaches, and patient characteristics, including clinical relevance and practical applicability. The IASLC has again assembled a large international database to permit multifaceted analysis. Providing confidence that the classification performs consistently in multiple settings, treatments, and patients requires consistent discrimination in multiple subset analyses. Although observed outcomes of patients in the 2011 to 2019 database are essential, considerations about how the classification will be used are also important to ensure clinical relevance and applicability. Conclusions: The strategy developed by the Staging and Prognostic Factors Committee is carefully designed to provide useful refinements to the stage classification of thoracic malignancies for the ninth edition of TNM classification of cancers.
KW - Lung cancer
KW - Lung cancer staging
KW - Non–small cell lung cancer
KW - Prognosis
KW - TNM classification
UR - http://www.scopus.com/inward/record.url?scp=85128321051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128321051&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.02.008
DO - 10.1016/j.jtho.2022.02.008
M3 - Article
C2 - 35278692
AN - SCOPUS:85128321051
VL - 17
SP - 806
EP - 815
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 6
ER -